
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April 2022.

Commission File Number: 001-40065

IM Cannabis Corp.

(Exact Name of Registrant as Specified in Charter)

Kibbutz Glil Yam, Central District, Israel 4690500

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

INCORPORATION BY REFERENCE

Exhibit 99.1 of this Form 6-K of IM Cannabis Corp. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-254255) of the Company, as amended or supplemented.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IM CANNABIS CORP.

(Registrant)

Date: April 14, 2022

By: /s/ Oren Shuster

Name: Oren Shuster

Title: Chief Executive Officer and Director

EXHIBIT INDEX

99.1 FORM 51-102F3 Material Change Report dated April 14, 2022

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

IM CANNABIS CORP. (the "Company")
Suite 2300 – 550 Burrard Street
Vancouver, BC, Canada, V6C 2B5

Item 2 Date of Material Change

April 6, 2022

Item 3 News Release

A press release disclosing the material change was disseminated on April 6, 2022 through the facilities of Canadian Newswire and subsequently filed on the Company's SEDAR profile at www.sedar.com.

Item 4 Summary of Material Change(s)

On April 6, 2022, the Company announced Focus Medical Herbs Ltd. ("**Focus Medical**"), an arm's length entity with which the Company has commercial agreements to cultivate and distribute products under the Company's brand, will close its Sde Avraham cultivation farm in Israel in the second quarter of 2022.

The closure is intended to allow the Company to enhance organizational efficiency, reduce operating costs and leverage its fully-licensed import-export supply chain for the import of medical cannabis from the Company's subsidiaries in Canada and from other third party suppliers.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On April 6, 2022, the Company announced new strategic imperatives designed to enhance organizational efficiency and reduce operating costs while further responding to the increased demand for premium, indoor-grown Canadian cannabis from Israeli consumers. As part of these changes, Focus Medical will close the Sde Avraham cultivation farm in Israel that it owns and operates. Focus Medical has an exclusive commercial agreement with IM Cannabis to distribute its production under the IMC brand. Focus Medical will complete the closure of the Sde Avraham cultivation farm during the second quarter of 2022.

The closure by Focus Medical of the Sde Avraham cultivation farm is intended to allow the Company to better leverage its fully-licensed import-export supply chain for the import of medical cannabis from the Company's subsidiaries in Canada and other suppliers. Focus Medical will also continue to concentrate on purchasing medical cannabis from third-party cultivation facilities in Israel and will rely on its existing inventory of proprietary genetics.

Pursuant to IFRS 10, the Company is viewed as effectively exercising control over Focus Medical, and therefore, the accounts of Focus Medical are consolidated with those of the Company. Focus Medical has an exclusive commercial agreement with IM Cannabis to distribute its production under the Company's IMC brand.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

Yael Harrosh
Chief Legal and Operations Officer
+972-54-6687515

Item 9 Date of Report

April 14, 2022